Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Jérôme Paillassa"'
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Hairy cell leukemia (HCL) and HCL-like disorders such as hairy cell leukemia variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL) are rare indolent B-cell malignancies. Purine analogs (PNAs), alone or in association with rituximab (R), are t
Externí odkaz:
https://doaj.org/article/9cb10799d96c41f69ac65c5dbd9cea49
Autor:
Jérôme Paillassa, Xavier Troussard
Publikováno v:
Cancer Reports, Vol 5, Iss 3, Pp n/a-n/a (2022)
Abstract Background Hairy cell leukemia (HCL) is a rare chronic B‐cell neoplasm with good long‐term prognosis. First and second‐line therapies include purine nucleoside analogues (PNAs) and rituximab, but until recently, limited alternative opt
Externí odkaz:
https://doaj.org/article/58c3c96a53094887886af1c25a4c9e3c
Autor:
Jérôme Paillassa, Firas Safa
Publikováno v:
Leukemia Research Reports, Vol 17, Iss , Pp 100282- (2022)
Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated with conventional therapies. Significant efforts have been made in recent years to bring a broad spe
Externí odkaz:
https://doaj.org/article/54dc16d21496498cb79761eb14519598
Autor:
Amélie Bachelot, Anne Bouvier, Jérémie Riou, Sylvain Thepot, Aurélien Giltat, Christopher Nunes Gomes, Jérôme Paillassa, Rébecca Jouanneau‐Courville, Maxime Renard, Annaelle Beucher, Laurane Cottin, Margaux Wiber, Bénédicte Ribourtout, Franck Geneviève, Damien Luque Paz, Aline Tanguy‐Schmidt, Valérie Ugo, Mathilde Hunault‐Berger, Odile Blanchet, Corentin Orvain
Publikováno v:
American Journal of Hematology. 98:922-931
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b86d6fd08e809d1cfbcbae2dc2651534
https://doi.org/10.1002/ajh.26917
https://doi.org/10.1002/ajh.26917
Publikováno v:
British Journal of Haematology
British Journal of Haematology, 2023, ⟨10.1111/bjh.18826⟩
British Journal of Haematology, 2023, ⟨10.1111/bjh.18826⟩
International audience; Obinutuzumab (GA101) is a humanized anti-CD20 monoclonal antibody used in the treatment of B-cell malignancies. Under rare occasions, obinutuzumab may induce acute and severe thrombocytopenia. However, little is known about th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::494376318c6784d9a541487de011b55e
https://doi.org/10.1111/bjh.18826
https://doi.org/10.1111/bjh.18826
Autor:
Nicolas Giachetti, Sarah Bellal, Marianne Schwarz, Jérôme Paillassa, Aline Clavert, Mathilde Hunault-Berger, Firas Safa
Background: Lymphomatoid granulomatosis (LYG) is a rare and atypical EBV induced B-cell lymphoproliferative disorder. Clinical manifestations are mainly respiratory, with nodular infiltrates, varying in number and size being responsible for respirato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc371d88199c6b6c0614225c98113cd7
https://doi.org/10.21203/rs.3.rs-2644436/v1
https://doi.org/10.21203/rs.3.rs-2644436/v1
Autor:
Kamel Laribi, Loic Ysebaert, Luca Inchiappa, Bruno Villemagne, Yann Guillermin, Jérôme Paillassa, Fatiha Merabet, Cécile Guénot, Alix Baugier de Materre, Charles Herbaux, Kristell Mahe, Marion Divoux, Caroline Algrin, Stephane Lepretre, Damien Roos Weil, Cécile Tomowiak, David Ghez, Stéphanie Poulain, Marion Loirat, Caroline Dartigeas, Lise Willems, Olivier Tournilhac, Marie C Bene
Publikováno v:
Blood. 140:1485-1487
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7532284556eed1c420b5e96d551e5d72
https://doi.org/10.1182/blood-2022-157399
https://doi.org/10.1182/blood-2022-157399
Publikováno v:
Current Oncology Reports. 24:1133-1143
This article aims to bring an update on the recent discoveries in hairy cell leukemia (HCL), especially findings in pathophysiology and therapeutic advances.Major discoveries have been made in genetics and epigenetics of HCL. Moreover, the importance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30292b577b051c0d0444df04d6849ec1
https://doi.org/10.1007/s11912-022-01285-1
https://doi.org/10.1007/s11912-022-01285-1
Autor:
Nadia Younan, Carole Soussain, Sylvain Choquet, Nathalie Cassoux, Valérie Touitou, Anna Schmitt, Olivier Chinot, Lucie Oberic, Gandhi Damaj, Roch Houot, Hervé Ghesquières, Kamel Laribi, Guido Ahle, Luc Taillandier, Jérôme Paillassa, Emmanuel Gyan, Fabrice Jardin, Vincent Delwail, Jean‐Pierre Marolleau, Adrian Tempescul, Philippe Agapé, Marie Bourniquel, Fabienne Vacheret, Ibrahim Jdid, Magali Le Garff‐Tavernier, Denis Malaise, Agusti Alentorn, Khê Hoang Xuan, Caroline Houillier
Publikováno v:
Hematological Oncology
Hematological Oncology, 2022, 40 (5), pp.976-986. ⟨10.1002/hon.3044⟩
Hematological Oncology, 2022, 40 (5), pp.976-986. ⟨10.1002/hon.3044⟩
Most relapses of primary central nervous system lymphoma (PCNSL) occur in the brain and are associated with a poor prognosis. Isolated intraocular relapses (IIORs) are rare and poorly described. We retrospectively selected from the French Lymphome Oc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aecaed90c3b3273887ae266d432b2a5e
https://hal-u-picardie.archives-ouvertes.fr/hal-03716518/document
https://hal-u-picardie.archives-ouvertes.fr/hal-03716518/document
Autor:
Baptiste Le Calvez, Benoit Tessoullin, Loïc Renaud, Carmen Botella-Garcia, Micha Srour, Steven Le Gouill, Gaelle Guillerm, Rémy Gressin, Stéphanie Nguyen Quoc, Sabine Furst, Adrien Chauchet, David Sibon, Philippe Lewalle, Xavier Poiré, Natacha Maillard, Alban Villate, Michael Loschi, Jérôme Paillassa, Yves Beguin, Rémy Dulery, Jean-Jacques Tudesq, Amandine Fayard, Marie C. Béné, Vincent Camus, Patrice Chevallier, Amandine Le Bourgeois
Publikováno v:
Acta Oncologica
Acta Oncologica, 2022, 61 (11), pp.1332-1338. ⟨10.1080/0284186X.2022.2130709⟩
Acta Oncologica, 2022, 61 (11), pp.1332-1338. ⟨10.1080/0284186X.2022.2130709⟩
Background: Despite therapeutic progress, 10 to 30% of adult patients with primary mediastinal B cell lymphoma (PMBCL) are primary refractory or experience early relapse (R/R). Allogeneic stem cell transplantation (allo-HSCT) thus remains a potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e692306229ca66cee810e88fc424cab
https://pubmed.ncbi.nlm.nih.gov/36214787
https://pubmed.ncbi.nlm.nih.gov/36214787